stoxline Quote Chart Rank Option Currency Glossary
Intensity Therapeutics, Inc. (INTS)
6.88  2.68 (63.81%)    12-08 16:00
Open: 8.61
High: 11.44
Volume: 31,734,433
Pre. Close: 4.2
Low: 6.26
Market Cap: 94(M)
Technical analysis
2023-12-08 4:44:06 PM
Short term     
Mid term     
Targets 6-month :  13.36 1-year :  15.6
Resists First :  11.43 Second :  13.36
Pivot price 3.02
Supports First :  5.61 Second :  2
MAs MA(5) :  4.16 MA(20) :  2.89
MA(100) :  4.37 MA(250) :  0
MACD MACD :  0.3 Signal :  -0.1
%K %D K(14,3) :  58.5 D(3) :  55.5
RSI RSI(14): 80.9
52-week High :  11.43 Low :  2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ INTS ] has closed above the upper band by 31.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.45 - 11.5 11.5 - 11.53
Low: 6.2 - 6.23 6.23 - 6.25
Close: 6.83 - 6.88 6.88 - 6.92
Company Description

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Headline News

Sat, 09 Dec 2023
Intensity Therapeutics rockets on positive INT230-6 data - The Pharma Letter

Fri, 08 Dec 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.36% By -

Fri, 08 Dec 2023
Why Is Intensity Therapeutics (INTS) Stock Up 133% Today? - InvestorPlace

Fri, 08 Dec 2023
Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today? - Intensity Therapeutics (NAS - Benzinga

Fri, 08 Dec 2023
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster ... - PR Newswire

Fri, 01 Dec 2023
2023-12-01 | NDAQ:INTS | Press Release | Intensity Therapeutics Inc - Stockhouse Publishing

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 14 (M)
Shares Float 8 (M)
Held by Insiders 15.9 (%)
Held by Institutions 0 (%)
Shares Short 4 (K)
Shares Short P.Month 3 (K)
Stock Financials
EPS -0.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.15
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -45.3 %
Return on Equity (ttm) -151.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -9.3
PEG Ratio 0
Price to Book value 5.93
Price to Sales 0
Price to Cash Flow -11.96
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android